atorvastatin + cilostazol + clopidogrel + prednisone + warfarin

This is a combination regimen consisting of five distinct pharmaceutical agents, each with different mechanisms of action and clinical indications: - **Atorvastatin** is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk by inhibiting the rate-limiting step in cholesterol biosynthesis. - **Cilostazol** is a phosphodiesterase III inhibitor that acts as an antiplatelet agent and vasodilator, primarily used for intermittent claudication. It increases cAMP levels in platelets and vascular smooth muscle, leading to inhibition of platelet aggregation and vasodilation[2][5]. - **Clopidogrel** is a thienopyridine-class antiplatelet drug that irreversibly inhibits the P2Y12 subtype of ADP receptor on platelets, reducing platelet aggregation. - **Prednisone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties. It modulates gene expression via the glucocorticoid receptor. - **Warfarin** is an oral anticoagulant that inhibits vitamin K epoxide reductase complex subunit 1 (VKORC1), thereby reducing synthesis of active vitamin K-dependent clotting factors II, VII, IX, X as well as proteins C and S[7][10]. This combination would have profound effects on lipid metabolism, platelet function/aggregation, inflammation/immunity modulation, and coagulation pathways.

Other names

atorvastatin calciumcilostazoleclopidogrel bisulfateprednisolone (active metabolite of prednisone)Jantoven (for warfarin)